” We have actually identified a formerly unidentified illness mechanism in ARVC, which includes a completely new layer of details that no one learnt about,” she says.
The previously unknown system is a problem in the nucleus, deep within the heart cells that are responsible for heart muscle contraction. The flaw sets off a domino effect that results in cell death.
” Based on the brand-new insights we acquired, we identified a particle that might have the ability to decrease disease development,” says Alicia Lundby from the Department of Biomedical Sciences at the University of Copenhagen.
Alicia Lundby and her associates studied heart biopsies from healthy individuals and from clients struggling with genetic ARVC. They carried out a so-called and deep molecular profiling of the heart samples and identified the molecular distinctions in between the hearts. Based upon these measurements, they developed hypotheses about the causes of the disease and checked them on mice models and stem cell-derived heart muscle cells.
The research study was just recently published in the journal Circulation.
Molecule from tulip tree as treatment?
The researchers discovered that by triggering a particular particle, sirtuin-3, they might slow down disease advancement. They, therefore, started a hunt for a molecule with that function.
And with honokiol, they discovered it. Honokiol is a natural product drawn out from the bark and leaves of the tulip tree and has actually been utilized e.g. as a pain reliever in traditional medication in some parts of Asia.
” When we tested honokiol on our mouse model, it actually did slow down the advancement of the illness. The very same occurred in our stem cell-derived heart cells. We do not know if it works the exact same with people, however the reality that we can validate the effect in two various designs makes it extremely interesting,” says Alicia Lundby.
” It is actually pleasing to take a job all the way from extremely basic science measurements, through interpretation of the results to coming up with a possible strategy to mitigate the illness development and lastly demonstrate that it works. To me, this is truly the essence of the kind of research I am thrilled about, particularly to shed light on the systems behind heart disease such that we can propose unique treatment methods,” she states.
” Doing the types of studies we do, analyzing numerous thousands of proteins at a time, is challenging when attempting to understand what the modifications we measure really mean. This part of the work requires diving into the clinical literature. You check out and read and read. And speak to coworkers, believe, and check out some more. It is months of investigator work. And its both stimulating and frustrating at times. Due to the fact that it is definitely not straightforward.”
The tough work does not stop here. The researchers have already introduced a follow-up research study to examine their findings more carefully.
” We believe our findings are significant, and we wish to determine whether they can in fact help patients. The next step for us is to figure out whether the mechanism we determined is present in all ARVC patients,” states Alicia Lundby.
Referral: “Loss of Nuclear Envelope Integrity and Increased Oxidant Production Cause DNA Damage in Adult Hearts Deficient in PKP2: A Molecular Substrate of ARVC” by Marta Pérez-Hernández, Chantal J.M. van Opbergen, Navratan Bagwan, Christoffer Rasmus Vissing, Grecia M. Marrón-Liñares, Mingliang Zhang, Estefania Torres Vega, Andrea Sorrentino, Lylia Drici, Karolina Sulek, Ruxu Zhai, Finn B. Hansen, Alex Hørby Christensen, Søren Boesgaard, Finn Gustafsson, Kasper Rossing, Eric M. Small, Michael J. Davies, Eli Rothenberg, Priscila Y. Sato, Marina Cerrone, Thomas Hartvig Lindkær Jensen, Klaus Qvortrup, Henning Bundgaard, Mario Delmar and Alicia Lundby, 12 August 2022, Circulation.DOI: 10.1161/ CIRCULATIONAHA.122.060454.
And in no time, millions of people all over the world were mindful of the danger presented by cardiovascular illness, the leading cause of death in the western world, according to the World Health Organization.
Alicia Lundby and her associates studied heart biopsies from healthy people and from clients suffering from genetic ARVC. They performed a so-called and deep molecular profiling of the heart samples and determined the molecular distinctions in between the hearts. Based on these measurements, they developed hypotheses about the causes of the disease and tested them on mice models and stem cell-derived heart muscle cells.
” When we checked honokiol on our mouse design, it actually did slow down the advancement of the disease.
By University of Copenhagen – The Faculty of Health and Medical Sciences
October 8, 2022
The researchers browsed for a particle that could slow disease progression– and they may have found it.
Conventional medicine could slow heart problem advancement.
Time stopped during the European Football Championship last summertime. When football gamer Christian Eriksen suddenly fell, died, and was resuscitated on live tv, the buzzing anxiety that had filled the air vanished in a matter of seconds. And in no time, millions of individuals all over the world understood the risk positioned by cardiovascular diseases, the leading cause of mortality in the western world, according to the World Health Organization.
When the heart fails in young athletes, the condition ARVC is frequently to blame. Half of all cases of abrupt cardiac arrest in athletes occurring throughout physical activity are believed to be caused by ARVC.
Researchers from the University of Copenhagen supply brand-new insights into a procedure included in the advancement of the disease in a recent research study. They likewise present a feasible treatment method, according to Professor Alicia Lundby, whose research study group led the new research study.
